Cover ImageSALE
市場調查報告書

全球蛋白質治療藥市場:2017∼2021年

Global Protein Therapeutics Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 345849
出版日期 內容資訊 英文 128 Pages
訂單完成後即時交付
價格
Back to Top
全球蛋白質治療藥市場:2017∼2021年 Global Protein Therapeutics Market 2017-2021
出版日期: 2016年12月30日 內容資訊: 英文 128 Pages
簡介

治療性蛋白質,廣泛使用作為蛋白質缺乏症等各種疾病、癌症、類風濕性關節炎等的治療。全球蛋白質治療藥市場,預計以2017∼2021年以7.86%的年複合成長率擴大。

本報告提供全球蛋白質治療藥市場相關調查,市場趨勢與課題,各產品,各治療領域,各蛋白質功能,及各地區趨勢,至2021年的市場成長預測,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 市場情況

  • 市場概要
  • 波特的五力分析

第6章 各產品市場區隔

  • 單株抗體
  • 胰島素注射液
  • 凝血因子
  • EPO
  • 人體生長荷爾蒙

第7章 各治療領域市場區隔

  • 代謝性疾病及內分泌疾病
  • 造血
  • 不孕症
  • 癌症
  • 自體免疫疾病
  • 感染疾病
  • 蛋白質疫苗

第8章 各蛋白質功能市場市場區隔

  • 酵素活性及控制活性
  • 特殊標的活性
  • 疫苗
  • 蛋白質診斷

第9章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第10章 推動市場的要素

第11章 促進要素的影響

第12章 市場課題

第13章 促進要素與課題的影響

第14章 市場趨勢

第15章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2016年
  • 其他值得注意的供應商

第16章 主要供應商分析

  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Amgen
  • AbbVie
  • Johnson & Johnson
  • Merck

第17章 附錄

第18章 關於Technavio

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR11316

About Protein Therapeutics

Therapeutic proteins are used to effectively treat a wide array of diseases such as protein deficiency diseases; chronic diseases such as cancer, rheumatoid arthritis (RA), ankylosing spondylitis, diabetes; infections such as human immunodeficiency virus (HIV), hepatitis A, hepatitis B, and hepatitis C; and other medical conditions such as genetic disorders, anemia cases related to kidney dialysis, and cancer-related anemia. Therapeutic proteins mostly consist of recombinant forms of naturally occurring proteins.

Technavio's analysts forecast the global protein therapeutics market to grow at a CAGR of 7.86% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global protein therapeutics market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and biosimilar drugs used for the treatment of various diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Protein Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Amgen
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novo Nordisk

Other Prominent Vendors

  • Anhui Anke Biotechnology (Group)
  • AstraZeneca
  • Baxter International
  • Biocon
  • Biodel
  • BioGenomics
  • Biopartners
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celltrion
  • Chugai Pharmaceutical
  • Diamyd Medical
  • Diasome Pharmaceuticals
  • DiaVacs
  • Dynavax Technologies
  • Eli Lilly
  • Ferring Pharmaceuticals
  • Generex Biotechnology
  • GeneScience Pharmaceuticals
  • Hualan Biological Engineering
  • Intas Pharmaceuticals
  • Ipsen
  • JCR Pharmaceuticals
  • Kyowa Hakko Kirin
  • Lexicon Pharmaceuticals
  • LG Life Sciences
  • MacroGenics
  • MannKind
  • Oramed Pharmaceuticals
  • Osiris Therapeutics
  • Pfizer
  • Sandoz International
  • Sanofi
  • Teva Pharmaceutical Industries
  • Thermalin Diabetes
  • Tolerion
  • Wockhardt
  • XOMA

Market driver

  • Increased demand for mAbs
  • For a full, detailed list, view our report

Market challenge

  • Complexities in manufacturing, storage conditions, distribution policies, and high cost
  • For a full, detailed list, view our report

Market trend

  • Emergence of next-generation biologics
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our procurement specialist's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Alternate therapies hinder the growth possibilities of approved therapies

PART 02: Scope of the report

  • Market overview
  • Assumptions
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Highlights

PART 05: Market landscape

  • Market overview
  • Five forces analysis

PART 06: Market segmentation by product type

  • Global mAbs market
  • Global human insulin market
  • Global clotting factors market
  • Global EPO market
  • Global human growth hormone market

PART 07: Market segmentation by therapy area

  • Metabolic and endocrine disorders
  • Hematopoiesis
  • Fertility
  • Cancer
  • Autoimmune diseases
  • Infectious diseases
  • Protein vaccine

PART 08: Market segmentation by protein function

  • Enzymatic and regulatory activity
  • Special targeting activity
  • Vaccines
  • Protein diagnostics

PART 09: Geographical segmentation

  • Protein therapeutics market in Americas
  • Protein therapeutics market in EMEA
  • Protein therapeutics market in APAC

PART 10: Market drivers

  • Increased demand for mAbs
  • Development of novel therapies using innovative technologies
  • Availability of favorable reimbursement policies

PART 11: Impact of drivers

PART 12: Market challenges

  • Complexities in manufacturing, storage conditions, distribution policies, and high cost
  • Complicated regulatory framework
  • Alternate therapies loom large

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Emergence of next-generation biologics
  • Advent of biosimilars expected to improve the treatment rates
  • Strategic alliances further boost the R&D efforts

PART 15: Vendor landscape

  • Competitive scenario
  • Market share analysis 2016
  • Other prominent vendors

PART 16: Key vendor analysis

  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Amgen
  • AbbVie
  • Johnson & Johnson
  • Merck

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Overview of protein therapeutics market 2016-2021
  • Exhibit 03: Key strategies in global protein therapeutics market
  • Exhibit 04: Global protein therapeutics market snapshot: Developed and emerging markets 2015
  • Exhibit 05: Global protein therapeutics market 2016-2021 ($ billions)
  • Exhibit 06: Patent expirations of major biologics 2000-2030
  • Exhibit 07: Impact of factors affecting the market 2016 and 2021
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Segmentation of global protein therapeutics market by product type
  • Exhibit 10: Market share of global protein therapeutics market by product type
  • Exhibit 11: Overview of global mAbs market
  • Exhibit 12: Annual treatment cost per patient for various drugs 2015
  • Exhibit 13: Global mAbs market: Present and future scenario
  • Exhibit 14: Global mAbs market 2016-2021 ($ billions)
  • Exhibit 15: Opportunity analysis of global mAbs market
  • Exhibit 16: Year-over-year (YoY) sales comparison of mAbs 2013-2015 ($ billions)
  • Exhibit 17: Market overview of human insulin
  • Exhibit 18: Global human insulin market 2016-2021 ($ billions)
  • Exhibit 19: Factors affecting global human insulin market
  • Exhibit 20: Opportunity analysis of global human insulin market
  • Exhibit 21: Revenues from the sales of top five products in insulin market 2013-2015 ($ billions)
  • Exhibit 22: Market overview of clotting factors
  • Exhibit 23: Global clotting factors market 2016-2021 ($ billions)
  • Exhibit 24: Opportunity analysis of global clotting factors market
  • Exhibit 25: Market overview of EPO
  • Exhibit 26: Global EPO market 2016-2021 ($ billions)
  • Exhibit 27: Globally approved EPO biosimilars
  • Exhibit 28: Opportunity analysis of global EPO market
  • Exhibit 29: Market overview of human growth hormone
  • Exhibit 30: Global human growth hormone market 2016-2021 ($ billions)
  • Exhibit 31: Opportunity analysis of global human growth hormone market
  • Exhibit 32: Segmentation of global protein therapeutics market by therapy area
  • Exhibit 33: Segmentation of global protein therapeutics market by protein function
  • Exhibit 34: Global protein therapeutics market: Segmentation by geography (2016-2021)
  • Exhibit 35: Global protein therapeutics market segmentation by region: Market growth lifecycle analysis 2016
  • Exhibit 36: Overview of protein therapeutics market in Americas
  • Exhibit 37: Protein therapeutics market in Americas 2016-2021 ($ billions)
  • Exhibit 38: Protein therapeutics market in Americas: Opportunity analysis
  • Exhibit 39: Overview of protein therapeutics market in EMEA
  • Exhibit 40: Protein therapeutics market in EMEA 2016-2021 ($ billions)
  • Exhibit 41: Protein therapeutics market in EMEA: Opportunity analysis
  • Exhibit 42: Overview of protein therapeutics market in APAC
  • Exhibit 43: Protein therapeutics market in APAC 2016-2021 ($ billions)
  • Exhibit 44: Protein therapeutics market in APAC: Opportunity analysis
  • Exhibit 45: mAb approvals by the US FDA and EMA 2010-2015
  • Exhibit 46: Advances in ADCs technology
  • Exhibit 47: Few of other technologies used in protein therapeutics
  • Exhibit 48: Impact of drivers
  • Exhibit 49: Approval process of biologicals versus biosimilars via Public Health Service Act (PHSA) in US
  • Exhibit 50: Few of CAM therapies used for autoimmune and inflammatory diseases
  • Exhibit 51: Impact of drivers and challenges
  • Exhibit 52: Overview of next-generation antibodies
  • Exhibit 53: Oral insulin pipeline portfolio
  • Exhibit 54: Few of the biosimilars under development
  • Exhibit 55: Key deals in global protein therapeutics market
  • Exhibit 56: Market presence of vendors in various therapy areas 2015
  • Exhibit 57: Competitive assessment of vendors
  • Exhibit 58: Geographical presence of key vendors
  • Exhibit 59: F. Hoffmann-La Roche: Profile
  • Exhibit 60: F. Hoffmann-La Roche: Strength assessment
  • Exhibit 61: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 62: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 63: Novo Nordisk: Profile
  • Exhibit 64: Novo Nordisk: Strength assessment
  • Exhibit 65: Novo Nordisk: Strategy assessment
  • Exhibit 66: Novo Nordisk: Opportunity assessment
  • Exhibit 67: Amgen: Profile
  • Exhibit 68: Amgen: Strength assessment
  • Exhibit 69: Amgen strategy assessment
  • Exhibit 70: Amgen: Opportunity assessment
  • Exhibit 71: AbbVie: Profile
  • Exhibit 72: AbbVie: Strength assessment
  • Exhibit 73: AbbVie: Strategy assessment
  • Exhibit 74: AbbVie: Opportunity assessment
  • Exhibit 75: Johnson & Johnson: Profile
  • Exhibit 76: Johnson & Johnson: Strength assessment
  • Exhibit 77: Johnson & Johnson: Strategy assessment
  • Exhibit 78: Johnson & Johnson: Opportunity assessment
  • Exhibit 79: Merck: Profile
  • Exhibit 80: Merck: Strength assessment
  • Exhibit 81: Merck: Strategy assessment
  • Exhibit 82: Merck: Opportunity assessment
Back to Top